High dose cyclophosphamide for severe refractory myasthenia gravis

High dose cyclophosphamide for severe refractory myasthenia gravis

Materials and methods All patients participated in studies approved by the Drexel University College of Medicine and signed informed consent. Drachman et al reported a decline in antibody levels in their patients treated in a similar way, although AChr antibody titres and MuSK antibodies persisted i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neurology, neurosurgery and psychiatry neurosurgery and psychiatry, 2004-05, Vol.75 (5), p.789-791
Hauptverfasser: Gladstone, D E, Brannagan, T H, Schwartzman, R J, Prestrud, A A, Brodsky, I
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Age
Amputation
Cyclophosphamide - administration & dosage
Cyclophosphamide - therapeutic use
Drug Administration Schedule
Drug Resistance
Dysphagia
high dose cyclophosphamide
Humans
Intubation
Letter
Male
myasthenia gravis
Myasthenia Gravis - drug therapy
Neutropenia
Patients
Severity of Illness Index
Stem cells
Steroids
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Materials and methods All patients participated in studies approved by the Drexel University College of Medicine and signed informed consent. Drachman et al reported a decline in antibody levels in their patients treated in a similar way, although AChr antibody titres and MuSK antibodies persisted in their patients even after 2 years. 1 This suggests that long term remissions in MG may be possible even without achieving complete immunoablation.
ISSN:0022-3050
1468-330X
DOI:10.1136/jnnp.2003.019232